KA
KLDO

Kerrisdale Advisers’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Kerrisdale Advisers’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-72,480
Closed -$546K – 43
2019
Q3 		$546K Hold
72,480
– – 0.34% 28
2019
Q2 		$841K Sell
72,480
-100
-0.1% -$1.46K 0.3% 23
2019
Q1 		$1.05M Buy
+72,580
New +$999K 0.2% 23

Other funds holding KLDO

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Kerrisdale Advisers's KLDO Position: Q4 2019 in Review

Kerrisdale Advisers sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q4 2019, closing a stake of 72,480 shares — an estimated $546K sold.

Kerrisdale Advisers first reported a position in KLDO in Q1 2019 and held it in 3 quarters. The position peaked at $1.05M in Q1 2019. 45 funds tracked by Wall St. Rank hold KLDO as of Q4 2019.

  • Kerrisdale Advisers reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Kerrisdale Advisers sold 72,480 Kaleido Biosciences, Inc. Common Stock shares in Q4 2019, an estimated $546K.
  • Kerrisdale Advisers first reported a position in Kaleido Biosciences, Inc. Common Stock in Q1 2019 and held it in 3 quarters.
  • Kerrisdale Advisers's Kaleido Biosciences, Inc. Common Stock position peaked at $1.05M in Q1 2019.
  • 45 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q4 2019.

Based on Kerrisdale Advisers's 13F filing for Q4 2019, filed 14 Feb 2020.